Five ways to beat German reimbursement
This article was originally published in Scrip
Germany's new reimbursement system has tripped up a lot of companies since it arrived in January 2011. Boehringer struggled with its diabetes drug Tradjenta and, fearing it wouldn't get a premium price, decided against launching in Germany. Other firms have mis-timed dossier filings, chosen the wrong comparative treatments, or ignored the advice of advisors. And the problem is only going to bigger as the reimbursement authorities start retrospective assessments of drug classes. There may be a map for the German process but this only helps companies through the administrative process. To perform properly, firms need to tune-up their organizations and reshape internal attitudes.